Pyrotinib + Xeloda vs. Tykerb + Xeloda for HER2+ MBC

Options

Experimental Pyrotinib and Xeloda Regimen Better Than Tykerb and Xeloda for Metastatic HER2-Positive Breast Cancer
May 26, 2020

Experimental pyrotinib and Xeloda offered better progression-free survival than Tykerb and Xeloda for people diagnosed with metastatic HER2-positive breast cancer who had previously been treated with Herceptin and chemotherapy. Read more...

Categories